文拉法辛是一種選擇性5-羥色胺和去甲腎上腺素重攝取抑制劑，自獲批上市以來，在臨床廣泛用于抑郁癥及抑郁癥狀和抑郁共病的治療。文拉法辛藥理作用機(jī)制主要是神經(jīng)遞質(zhì)和神經(jīng)可塑性，臨床上用于治療抑郁和抑郁共病，臨床不良事件包括藥物起效滯后、不良反應(yīng)和藥物相互作用。就文拉法辛與抑郁治療相關(guān)的機(jī)制研究及其臨床應(yīng)用和不良事件反饋進(jìn)行綜述。

Venlafaxine, a serotonin-norepinephrine reuptake inhibitor, has been widely used in the clinical treatment of depression, depressive symptoms and depression comorbidities since its approval. The pharmacological mechanism of venlafaxine is mainly neurotransmitter and neuroplasticity. Venlafaxine is used in treatment of depression and depression comorbidities. The clinical adverse events of venlafaxine include delayed drug onset, adverse reactions, and drug interactions. This article reviews the mechanism study, clinical practice, and the adverse events of venlafaxine.

R964

國家自然科學(xué)基金資助項目（82073922，81872930，81673505）；江蘇省“333”工程培養(yǎng)資金資助項目（BRA2020287）；中國藥科大學(xué)“雙一流”高校建設(shè)項目（CPU2018GY22）